Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN-AGE
2023-510354-16-00Phase 4Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of Prevnar 20 and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease (4 arms), sponsored by Leiden University Medical Center. Planned start Jan 2025; status: authorised.
02
Drugs
Prevnar 2023-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2023-510354-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510354-16-00.